Merck (NYSE: MRK) secured a clean sweep in U.S. patent reviews and a German court lifted a sales ban on subcutaneous Keytruda, clearing dual commercial paths for the flagship franchise as intravenous exclusivity erodes.
The U.S. Patent Trial and Appeal Board invalidated all challenged claims in two Halozyme (NASDAQ: HALO) patents — No. 12,077,791 and No. 12,195,773 — marking the 14th win in 14 instituted post-grant reviews Merck has brought against the San Diego biotech, Fierce Pharma reported. The Munich Higher Regional Court overturned a December 2024 preliminary injunction that had blocked Keytruda Qlex in Germany, Europe’s largest pharmaceutical market.
“Overall, I just want to emphasize, we feel very strongly that we have IP that gives us freedom to operate as it relates to Qlex,” Merck Chief Executive Rob Davis told analysts on the third-quarter earnings call. “Nothing has changed to our confidence we see long term.”
Merck Prevails in Patent Reviews Weakening Infringement Case
- Merck has now prevailed in all 14 instituted U.S. post-grant reviews against Halozyme’s MDASE patent portfolio, weakening the infringement case pending in New Jersey federal court.
- Keytruda Qlex generated $830 million in Q3 2026 — 9.7% of total Keytruda revenue — with U.S. sales of $693 million accounting for 83.5% of the subcutaneous total.
- A Dutch injunction covering eight European markets remains in force, creating a fragmented commercial map for the subcutaneous formulation across the continent.
U.S. Patent Wall Holds — For Now
The PTAB decisions, issued Wednesday, target the enzyme platform Halozyme calls MDASE. Merck argued the patent claims were excessively broad and supported by insufficient experimental data, a position the board adopted across both reviews.
The rulings cover the hyaluronidase variants Halozyme asserts are infringed by ALT-B4, the recombinant enzyme developed by South Korea’s Alteogen (KOSDAQ: 196170) and licensed to Merck in a 2020 deal worth up to $1 billion in milestones plus a 2% royalty on net sales after milestones are met.

Merck filed the first post-grant reviews in November 2024. Halozyme responded with a federal infringement suit in the District of New Jersey in April 2025, which has been stayed pending the PTAB outcomes. Six of Merck’s challenges remain marked “pending director review” at the USPTO, and Halozyme retains the right to appeal the final written decisions to the U.S. Court of Appeals for the Federal Circuit.
German Door Reopens, Dutch Lock Stays Shut
The Munich court’s reversal allows Merck to launch Keytruda Qlex in Germany roughly one year after the European Commission granted marketing authorization in November 2024. Halozyme’s Chief Legal Officer Mark Snyder said the company “disagrees with the court’s decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief,” according to a Nov. 19 statement cited by biz.chosun.com.
That German proceeding and the Dutch case rest on different European patents. The Hague’s specialized patent court ruled in October 2026 that Keytruda Qlex infringes Halozyme’s EP 2,797,622, rejecting Merck’s invalidity defense and barring manufacture, sale, and import across Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The German appeals court’s decision does not affect that order, biz.chosun.com reported.
Keytruda Qlex Sales Grow Through Subcutaneous Formulation
Keytruda Qlex launched in the United States in late September 2025. Third-quarter sales of $830 million represented a 79.3% sequential increase from Q2, en.sedaily.com noted. The subcutaneous formulation converts a 30-minute intravenous infusion into a roughly five-minute injection, a switching dynamic Merck is counting on to preserve volume as U.S. biosimilar competition approaches the intravenous product.

| Metric | Q3 2026 | Share of Keytruda Franchise |
|---|---|---|
| Keytruda Qlex Global Sales | $830 million | 9.7% |
| U.S. Qlex Sales | $693 million | 83.5% of Qlex |
Alteogen’s milestone payments are tied to Qlex sales thresholds. Merck has not disclosed a German launch date.
Next Steps on Two Continents
In the United States, the New Jersey infringement suit remains stayed; the Federal Circuit appeal clock starts when the PTAB issues final written decisions. In Germany, Halozyme’s promised permanent-injunction suit will test the same patent family the Munich court just declined to enforce preliminarily. The Dutch order remains enforceable unless overturned on appeal. Merck and Halozyme did not respond to Fierce Pharma’s requests for comment.
Merck traces its roots to a Darmstadt pharmacy opened in 1668 by Friedrich Jacob Merck; in 1827 the German parent began commercial morphine production. The U.S. affiliate was founded in 1891 with $200,000 from E. Merck and operated as a subsidiary until expropriation under the Trading with the Enemy Act in 1917.
George F. Merck repurchased it at auction in 1919 for $3.5 million, creating an independent company that retains the Merck name in the United States and Canada while the original German group holds rights elsewhere. In 2024, Keytruda generated $29.5 billion, or 46% of total revenue, making it the primary engine of the company now ranked fifth among biomedical firms by sales.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.